GSK To Acquire Nuvalent For $10.6bn In Cancer Drug Push
GSK agrees to acquire Nuvalent for $10.6bn, strengthening its position in cancer drug development and expanding its oncology pipeline. GSK has agreed to acquire US listed biotech company Nuvalent in a $10.6 billion all cash transaction, signalling a stronger push into oncology as the drugmaker reshapes its long-term growth strategy...
Read more